Document is current
Any future updates will be listed below
-
Authors
Liu, Mengyi
Ji, Zhicheng
Jain, Vaibhav
Smith, Vanessa L.
Hocke, Emily
Patel, Anoop P.
McLendon, Roger E.
Ashley, David M.
Gregory, Simon G.
López, Giselle Y.
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (1KL2TR002554)
National Cancer Institute (5P50CA190991)
- License Information
-
More Information
Article History
Received: 1 February 2024
Accepted: 30 March 2024
First Online: 22 April 2024
Declarations
:
: Ethical approval for the studies was received from the Duke Institutional Review Board. The studies were determined to be exempt (Pro00105756).
: Not applicable.
: APP is a consultant for and has an equity interest in Sygnomics, and APP and GYL are consultants for Servier Pharmaceuticals; these are unrelated to the research presented herein. The remaining authors have no relevant competing interests to declare.
